Two Standardized Radial Pressure Wave Techniques Versus Pain-Site Guided Therapy in Patients With Knee Osteoarthritis.

April 23, 2026 updated by: Armando Tonatiuh Avila Garcia, Hospital Civil de Guadalajara

Double-Blind Randomized Controlled Trial Comparing the Effectiveness of Two Standardized Radial Pressure Wave Techniques Versus Pain-Site Guided Therapy in Patients With Knee Osteoarthritis.

The goal of this clinical trial is to evaluate and compare the effectiveness of radial pressure wave therapy (RPWT) applied at different anatomical sites in patients with knee osteoarthritis (OA) over a follow-up of four months. The main questions it aims to answer are:

How effective is the application of RPWT on the medial and lateral interarticular lines in patients with knee OA? Are standardized RPWT application techniques on interarticular lines superior to the traditional application technique on the points of greatest pain in patients with knee OA?

Researchers will compare the effectiveness of two standardized application techniques on interarticular lines to decrease pain and improve function in patients with knee OA.

Participants will receive three sessions of RPWT on the most painful knee as a result of knee OA.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Methods Patients The study will enroll patients between the ages of 50 and 80 years with chronic and current knee pain and a clinical and radiographic diagnosis of knee osteoarthritis (OA). Participants will be recruited through the "Treatment of Knee OA with Radial Pressure Wave Therapy" campaign conducted by the Physical Medicine and Rehabilitation Department of the Hospital Civil de Guadalajara "Fray Antonio Alcalde" in México. Recruitment will take place during the months of August and September 2024. Individuals with a history of knee surgery, inflammatory arthritis, septic arthritis, fibromyalgia, cancer, or severe vascular insufficiency will be excluded from participation in this study.

Ethical Statement The participants will be required to sign an informed consent form which will include all details of the study. The patients will be free to decide whether or not to participate or to withdraw from the protocol at any time. The study was approved by the Research Ethics Committee of the Hospital Civil de Guadalajara Fray Antonio Alcalde (number: CEI 157/24) and was conducted in accordance with the World Medical Association's Declaration of Helsinki.

Randomization After obtaining written informed consent, the participants will be randomized to one of three treatment groups: radial pressure wave therapy (RPWT) at the two most painful points (control group), RPWT at the medial interarticular line (medial group), or RPWT at the medial and lateral interarticular lines (medial and lateral group). Randomization will be performed using the paper envelope randomization method. For this purpose, the investigators will prepare a series of opaque papers, each indicating one of the three possible assignments. These papers will be placed in an opaque bag, and during the enrollment process, each patient will randomly draw a paper from the bag. The patient's group assignment will be determined by the label on the paper drawn.

Treatment The three groups will receive RPWT using the BTL-6000 Radial Shockwave Therapy device (BTL Industries, Ltd.). Each patient will receive 3 sessions of RPW, once a week, in the supine position with knee flexion of 30 to 60 degrees, 2,000 pulses per session, 2.0 bar, and frequency of 10 Hz. The air pressure and frequency will be adjusted according to discomfort. The control group will receive 1,000 pulses to the two most painful areas of the treated knee, according to the technique used in most previous studies in this area. The medial group will receive 2,000 pulses at the medial interarticular line of the treated knee, while the medial and lateral groups will receive 1,000 pulses at the medial interarticular line and 1,000 pulses at the lateral interarticular line of the treated knee. All participants will be trained to perform a home exercise program for 4 consecutive weeks, three sessions per week, consisting of superficial thermotherapy for 10 minutes, hamstring and quadriceps stretching, medial gluteus medius and quadriceps strengthening, and propioception exercises. The interventions will be performed at the Physical Medicine and Rehabilitation Department of the Civil Hospital of Guadalajara "Fray Antonio Alalde". Complications, adverse effects and complaints during treatment will be documented.

Outcome measures A questionnaire will be used to assess sociodemographic characteristics, including age, gender, and education level for all patients. In addition, the numerical and categorical forms of body mass index (BMI), physical activity habits, and analgesic use will be assessed after eligibility criteria are established using the aforementioned instrument. The severity of knee OA will also be measured by a board-certified rheumatologist using the Kellgren & Lawrence scale.

The Spanish version of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) will be used to assess self-reported disability. The WOMAC is a disease-specific, self-administered questionnaire developed for patients with knee OA and takes approximately 5 minutes to complete. It has a multidimensional scale consisting of 24 items grouped into three dimensions: pain (five items), stiffness (two items), and physical function (17 items). We will use the Likert version with five response levels for each item, representing different levels of intensity (none, mild, moderate, severe or extreme) that are scored from 0 to 4. The final score for the WOMAC questionnaire is determined by adding the aggregate scores for pain, stiffness and function. The higher the score, the worse the patient's condition; therefore, improvement is achieved by reducing the total score. The data were standardized to a range of 0 to 100, with 0 representing the best possible health status and 100 representing the worst possible status. Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS), a world-renowned instrument consisting of a linear scale with numbered intervals from zero (no pain) to ten (the worst pain) that patients use to quantify their current pain intensity. It is well known that pain is the most important symptom of knee OA. Therefore, pain will be the primary outcome measure in the study. Treatment success was defined as an individual improvement in the NPRS of 50% from baseline. Evaluations will be performed at baseline, at the end of the third session, at 2 months, and at 4 months after the first RPWT session.

Blinding This study will use a double-blind design in which both the participants and the clinical evaluator responsible for performing the clinical and radiographic assessments will be blinded to the group assignments. Participants will be informed that they may receive one of the three possible treatment options, but will not know which specific technique will be applied to them. The RPWT will be performed by a final year resident in Physical Medicine and Rehabilitation who will be aware of the group assignments but will not be involved in the outcome assessments. To ensure further blinding, data collection and analysis personnel will also be blinded to the intervention groups. All treatment sessions will be conducted under standardized conditions with identical instructions, setup, and environment for all groups to reduce potential bias.

Sample size calculation Pain intensity, as measured by the NPRS, was considered the primary outcome measure for sample size determination. The investigators used a significance level of 0.05 (two-tailed) and statistical power of 80% (1-β), corresponding to Z values of 1.96 and 0.84, respectively. The calculation was based on an expected effect size of 2.0, considered clinically relevant based on previous studies, and a standard deviation of 2.1 reported in the literature. The initial calculation indicated that approximately 17 participants per group would be required. To account for an expected 20% loss to follow-up, the investigators adjusted the sample size and increased it to 23 participants per group to ensure the robustness and validity of the results. In summary, a total of 23 patients will be recruited for each of the three groups in our study, taking into account both the expected effect size and the adjustment for loss to follow-up.

Statistical Analysis Data will be analyzed using the Statistical Package for the Social Sciences (SPSS) version 22.0 software. Normality of the data distribution was assessed using the Kolmogorov-Smirnov test. For variables with a normal distribution, the mean and standard deviation will be calculated; for variables with a non-normal distribution, the median and interquartile range (IQR) will be reported. Qualitative data are presented as numbers and percentages. In cases of normal distribution, a t-test will be used to analyze differences within and between groups. One-way ANOVA will be used to determine statistical differences in WOMAC questionnaire and NPRS scores over the course of the study. Pearson's correlation coefficient will be used to assess the relationship between the 4th month scores (WOMAC and NPRS), baseline scores, age, BMI, and Kellgren & Lawrence severity grades. The strength of the correlation is classified as negligible (0.00-0.10), weak (0.10-0.39), moderate (0.40-0.69), strong (0.70-0.89), and very strong (0.90-1.00). All tests are considered statistically significant at a p-value of ≤0.05.

Study Type

Interventional

Enrollment (Actual)

82

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44280
        • Hospital Civil de Guadalajara Fray Antonio Alcalde

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Chronic and current knee pain.
  • Clinical and radiographic diagnosis of knee OA.

Exclusion Criteria:

  • History of knee surgery.
  • Inflammatory arthropathy.
  • Septic arthritis.
  • Fibromyalgia.
  • Cancer.
  • Severe vascular insufficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The control group will receive 1,000 pulses at the two most painful sites of the treated knee, in accordance with the technique employed in the majority of previous studies in this field.
Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)
Experimental: Medial group
The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The medial group will receive 2,000 pulses at the medial interarticular line of the treated knee.
Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)
Experimental: Medial and lateral group
The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The medial and lateral group will receive 1,000 pulses at the medial interarticular line and 1,000 pulses at the lateral interarticular line of the treated knee.
Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Intensity
Time Frame: Baseline and 4 months after the first session (final follow-up assessment).
Pain intensity was assessed using the 11-point Numeric Pain Rating Scale (NPRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Data correspond to the 4-month follow-up assessment.
Baseline and 4 months after the first session (final follow-up assessment).
Self-reported Disability
Time Frame: Four months after the first session (final follow-up assessment).

Self-reported disability measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a disease-specific, self-administered questionnaire designed for patients with knee osteoarthritis. It consists of 24 items grouped into three subscales: pain (5 items), stiffness (2 items), and physical function (17 items). The Likert version was used, with five response levels for each item (none, mild, moderate, severe, or extreme), scored from 0 to 4. The total score is obtained by summing all item scores, with higher values indicating greater disability. Scores were standardized to a 0-100 scale, where 0 represents the best possible health status and 100 the worst.

WOMAC was assessed at baseline, after treatment, and at 2- and 4-month follow-ups. The data reported correspond to the final 4-month assessment, representing the main time point for analysis.

Four months after the first session (final follow-up assessment).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Tonatiuh Avila, MD, Hospital Civil de Guadalajara

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2024

Primary Completion (Actual)

January 31, 2025

Study Completion (Actual)

February 28, 2025

Study Registration Dates

First Submitted

September 20, 2024

First Submitted That Met QC Criteria

September 30, 2024

First Posted (Actual)

October 2, 2024

Study Record Updates

Last Update Posted (Actual)

May 15, 2026

Last Update Submitted That Met QC Criteria

April 23, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CEI 157/24

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data supporting the findings of this study are available from the lead author upon reasonable request by email.

IPD Sharing Time Frame

From February 2025 to February 2026.

IPD Sharing Access Criteria

  1. Qualified researchers who have received IRB approval.
  2. Prior reasonable request by email.
  3. Data will be made available by PDF files or other non-editable formats.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.